Crisil reaffirms 'A1+' rating on Ranbaxy Laboratories bank facilitiesCrisil has reaffirmed its 'A1+' rating on bank facilities of Ranbaxy Labs post Sun Pharma announcement to acquire 100 per cent stake in it.
Sun Pharma’s acquisition: Is this the end of road for the 50-plus-year brand Ranbaxy?Former Ranbaxy officials lament that rival Sun Pharma’s acquisition of the co would mark the death of the brand, which has been ailing for ...
Sun Pharma-Ranbaxy deal: Daichi Sankyo failed to harness the complexities of a strong generic business, says Malvinder SinghThe Sun-Ranbaxy combined entity will unlock the true potential of the Gurgaon based company, says former Ranbaxy owner Malvinder Singh.
Sun Pharma to buy Ranbaxy in $3.2 bn deal: HighlightsSun Pharmaceutical Industries said that it will buy generic drug maker Ranbaxy Laboratories, has hit regulatory snags in its key US market ...
'Former Ranbaxy shareholders hid key info on US investigation'Ranbaxy's Japanese promoters today blamed the company's former Indian owners for concealing and misrepresenting critical information about ...
Ranbaxy has taken steps to ensure quality control: Arun SawhneyRanbaxy Laboratories today said it has taken several steps in recent years to ensure safety and efficacy of its products in the global mark...
- Ranbaxy Q3 top-line seen up 33% at Rs 2698 crore
Ranbaxy is expected to report a 33 per cent jump in its net sales for the quarter ended September 30 to Rs 2698 crore.
- Ranbaxy launches generic version of Evoxac in US market
Ranbaxy has launched generic cevimeline hydrochloride capsules, used in treating Sjogren's syndrome, in the US market.
- Daiichi Sankyo and Ranbaxy Launch hybrid business in Venezuela
Daiichi Sankyo & Ranbaxy announced that Daiichi Sankyo Venezuela would begin marketing Ranbaxy products in Venezuela as part of hybrid busi...
- Ranbaxy opens new manufacturing facility in Morocco; eyes $1 bn drug market
Ranbaxy has opened a new production facility in Morocco, a move which would help the drug maker access the African nation's $1 billion phar...
Ranbaxy laboratories may hand over Latin American operations to Daiichi SankyoRanbaxy may hand over its L American mkting operations to Daiichi Sankyo, a move could be a precursor to the Indian drugmaker's exit from s...
- Ranbaxy to sell Daiichi Sankyo product in Malaysia
Drug firm Ranbaxy Laboratories and Japan's Daiichi Sankyo today said Ranbaxy will market its parent company's products in Malaysia.
- Ranbaxy: Less aggressive, more Japanese and more healthy after 3 years under Japan's Daiichi
Under Daiichi, Ranbaxy is emerging as a less aggressive, less confrontational, less communicative and more Japanese and more healthy.
- Daiichi to use Ranbaxy network to sell products in Singapore
Ranbaxy and Daiichi Sankyo had signed a three-year plan to exploit synergies in operations to enhance their generic as well as branded busi...
- Would book partial profits on Ranbaxy: Sameer Shetye, AK Stockmart
Ranbaxy has been moving in a upward rising wedge and has taken resistance at upper trend line of the wedge.
- Ranbaxy transfers R&D unit to Daiichi Sankyo
Ranbaxy Laboratories has transferred its research division for new drugs to Japan’s Daiichi Sankyo turning Ranbaxy into a pure generic drug...
- Daiichi's own man to head Ranbaxy quality
Japan's Daiichi Sankyo has named an executive with more than 25 years of experience to oversee the quality and manufacturing standards in R...